PVCT Provectus Biopharmaceuticals - Winner of Best New Concept Award - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message


Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4596 of 5340  at  8/24/2019 11:38:50 AM  by


 In response to msg 4593 by  leave_the_gun
view thread

Re: Winner of Best New Concept Award

This award can only be viewed as a positive development that provides needed third party validation from a body whose qualifications & motives are indisputable. 
Having said that, it's unlikely the award will launch the proposed trial onto any kind of well-funded fast-track.  For example, here's a summary of what's happened with the proposal that won the 2014 'Best of New Concepts' award: 
“A randomised Phase2/3 study of infusional FU/LV with panitumumab V FU/LV/capecitabine with bevacizumab as first line therapy for never resectable, RAS and RAF wild type metastatic colorectal cancer.” 
- won Best New Concept Award in 2014
- a 2015 grant request to the AGITG Innovation Fund for $100k in funding was denied
- a 2016 grant request was successful, amount unknown
- pilot phase for MONARCC Study commenced in 2017
Here's a link to a summary of the trial, with centers located strictly in Australia: 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 277
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by